Navigation Links
Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
Date:2/11/2008

LEVERKUSEN, Germany and MINNEAPOLIS, Minnesota, February 11 /PRNewswire/ -- Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA and Possis Medical, Inc., Minneapolis, MN, (Nasdaq: POSS), announced today that they have entered into a definitive merger agreement pursuant to which MEDRAD will acquire Possis Medical in a cash tender offer for US-Dollar 19.50 per share, or a total equity value of approximately US-Dollar 361 million. The offer price represents a premium of approximately 39 percent over Possis Medical's average closing price for the thirty days prior to February 8, 2008. The board of directors of Possis Medical has unanimously approved the transaction and resolved to recommend the offer to their shareholders.

The transaction is structured as a tender offer, which the parties have agreed to commence within the next ten business days followed by a merger. Both the tender offer and the merger are subject to terms and conditions detailed in the merger agreement, including the tender of not less than two-thirds of the outstanding shares of Possis Medical on a fully-diluted basis and customary regulatory clearances. The tender offer is not subject to a financing contingency. The tender is to be followed by a second-step merger in which any untendered Possis Medical shares would be converted into the right to receive the same price per share as shareholders who tendered in the cash tender offer. The tender offer is expected to close in the first quarter of 2008.

MEDRAD is a leading provider of contrast injection systems used to diagnose cardiovascular and other diseases. Possis Medical is a leading provider of mechanical thrombectomy devices used to treat narrowed or blocked arteries and veins. The proposed combinatio
'/>"/>

SOURCE Bayer HealthCare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
2. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
3. Bayer CropSciences Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed
4. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
5. L&M Healthcare Communications, LLC, Hires Scott Karasinski, PharmD
6. DiObex, Inc. to Present at Merrill Lynch Global Healthcare Conference
7. Intellisphere Announces Acquisition of Multiple Titles from Ascend Medias Healthcare Division
8. inVentiv Health to Present at the 2008 UBS Global Healthcare Services Conference
9. Halogen Advances its Lead in Providing Employee Performance and Talent Management Solutions for the Healthcare Market
10. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
11. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 Cytokinetics, Incorporated (Nasdaq: ... February 28 with patients and health care advocates in ... Rare Disease Day®. Rare Disease Day is dedicated ... attention to the special challenges faced by patients with ... “Cytokinetics is proud to stand alongside patients and caregivers ...
(Date:2/26/2015)... , Feb. 26, 2015 On behalf of ... affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... lawsuit against Genewiz Inc. in excess of $10 million. ... GenScript,s trade secrets, and that it improperly hired one ... order denying motions for judgment notwithstanding the verdict, a ...
(Date:2/26/2015)...   Regulus Therapeutics Inc . (NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... Executive Officer of Regulus, will present a company overview ... Healthcare Conference on Wednesday, March 4, 2015 at 9:20 ... Boston Marriott Copley Place.  The presentation ...
(Date:2/26/2015)... On behalf of biotech client GenScript USA, ... & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript’s ... for judgment notwithstanding the verdict, a new trial, and ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... (NASDAQ: CPHD ) today announced that, together ... Jersey (UMDNJ), it has received a grant from the ... amplification methods for highly-sensitive detection of bloodstream bacteria using ... The $1.3 million grant is for the first year ...
... 19, 2012   Organovo Holdings, Inc. (OTCQB: ONVO) ... $15.2 million private placement. At the final closing, the ... sale of 6.9 million Units, at a price of ... approximately 43.7 million shares of common stock issued and ...
... of the world,s leading environmental scholars are sounding the alarm ... environmental institutions into a more coherent and robust planetary stewardship ... changes to the Earth,s subsystems. University of ... of a paper which appears in Science on ...
Cached Biology Technology:Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 2Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 3Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 4Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 2Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 3Scholars call for global governance overhaul to ensure Earth's sustainability 2
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to their ... technology is to ensure that an individual is who she/he ... may make use of a person,s unique physical characteristics, such ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... COLUMBIA, Mo. Millions of post-menopausal women use hormone ... associated with menopause. In a recent University of Missouri ... in HRT, a synthetic progestin, could be a major ... the researchers have compelling evidence that using an antibody ...
... What: Challenges and Promise of ... research in regenerative medicine using stem cells. The opening ... cell therapy. This will be followed by four plenary ... of neurological, cardiac, musculoskeletal, and metabolic diseases and disorders. ...
... Will April be the cruelest month? , ... are eerily reminiscent of 1993 and 1994, back-to-back years of serious ... of economic damage, damaging and destroying more than 50,000 homes and ... Parallels this year include abnormally high levels ...
Cached Biology News:MU researcher links hormone replacement therapy to breast cancer 2Challenges and promise of cell-based therapies 2Geologist decries floodplain development 2Geologist decries floodplain development 3
Anti-HumanLactoferrin...
Rabbit monoclonal [EP881Y] to EEF2K ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminal of human EEF2K. Entrez GeneID: 29904 S...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
Biology Products: